Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

Korábbi kezelés

• Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;

Más betegség

• Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;

Egyéb

• Pregnant or lactating women

• Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;
• Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
• Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted;
• Patient is willing and able to adhere to the study visit schedule and other protocol requirements;
• Patient has recieved complete remission and has completed planed courses of chemotherapy
• Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if bone marrow (BM) involvement by lymphoma)；Platelet ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if BM involvement by lymphoma)； Hemoglobin ≥ 8 g/dL. Anticipated life expectancy at least 3 months